A multi-billion-dollar acquisition within the radiopharmaceutical space could be percolating as Lantheus Holding considers a buyout offer from Curium Pharma, Bloomberg
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…
Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a…
Amid restructuring efforts, Bayer has addressed its need for a capital infusion in pharma under a deal
